|
57 Products |
| 57 Products |
|
190 Diseases |  |
10960 News |  |
| «12...7891011121314151617...105106» |
- | fingolimod / Generic mfg.
Journal: Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses. (Pubmed Central) - Jan 28, 2024
Last, analyses of proteomic databases of MS samples identified Ana peptides to be more abundant in the cerebrospinal fluid (CSF) of human MS patients with high disease activity. A role for Ana in MS as a consequence of a lack of astrocytic TIMP-1 production could influence both the efficacy of fingolimod responses and innate remyelination potential in the MS brain.
- | Mavenclad (cladribine) / EMD Serono
Journal: Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis. (Pubmed Central) - Jan 26, 2024
We also obtained numerous potential interactions for Bruton's tyrosine kinase inhibitors that are in clinical development for MS, such as evobrutinib (n = 434 DDIs)...We demonstrate that deep learning techniques can exploit chemical structure similarity to accurately predict DDIs and DFIs in patients with MS. Our study specifies drug pairs that potentially interact, suggests mechanisms causing adverse drug effects, informs about whether interacting drugs can be replaced with alternative drugs to avoid critical DDIs and provides dietary recommendations for MS patients who are taking certain drugs.
- Zeposia (ozanimod) / BMS
ECCO Grant Dissecting the role of S1PR1 modulator in the mucosal regeneration of Ulcerative Colitis () - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_2086;
Anticipated Impact In short and medium term, we will improve the knowledge on the role of S1PR1 in the processes of mucosal healing and identify the molecular pathways involved in the response to the mucosal damage mediated by the ozanimod in non-immune cells. The results of this study may improve the treatment options for UC patients.
- Burden of herpes zoster in patients with inflammatory bowel disease treated with immunosuppressive agents (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1998;
Additional treatments included anti-interleukin (IL)-23 agents (risankizumab, ustekinumab, mirikizumab) and sphingosine-1-phosphate (S1P) receptor modulators (etrasimod, ozanimod)...Conclusion Patients with IBD of all ages, but specifically those aged <50 years, are at higher risk of HZ compared with non-IBD cohorts, and IS medications contribute to this risk. Vaccination against HZ prior to initiating IS treatment could benefit patients with IBD.
- Zeposia (ozanimod) / BMS
Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1915;
Conclusion Clinical responders after 1 y on OZA sustained response for an additional 3 y and achieved clinical remission with continuous OZA exposure. OZA is a safe, tolerable, and durable therapy for pts with UC.
- Zeposia (ozanimod) / BMS
Ozanimod-Exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Histologic Changes in Lymph Nodes (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1869;
These changes could be in keeping with the known mechanism of action of ozanimod and suggests that other inflammatory pathways were driving their disease activity in these patients. The significance of the changes, particularly the Castleman-like features, needs to be further investigated.
- Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis: A Systematic Review and Network Meta-analysis (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1828;
Furthermore, etrasimod, filgotinib and tofacitinib ranked high in achieving these outcomes. This study highlights the role of small molecules drugs as effective alternatives to biologics.
- Velsipity (etrasimod) / Pfizer
Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: Data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1777;
P3
This study highlights the role of small molecules drugs as effective alternatives to biologics. Conclusion This post hoc analysis further characterises the efficacy and safety of etrasimod as a first-line advanced treatment after conventional 5-ASA and/or thiopurine therapy, and is consistent with previous results in the cohort of pts na
- Zeposia (ozanimod) / BMS, Rinvoq (upadacitinib) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Appropriateness of small molecule agents for patients with IBD of childbearing age (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1762;
9.If a woman conceives while taking TFUO, the medication should be ceased, she should receive counselling about potential known and unknown maternofoetal complications, and alternative IBD therapy may be commenced if required. Conclusion We developed 13 practice statements derived from a RAND appropriateness panel of clinicians and patients to guide decision making for women of childbearing age regarding TFUO small molecules therapies for IBD.
- Velsipity (etrasimod) / Pfizer
Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52 trial (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1747;
Conclusion In line with the described role of S1PR in lymphocyte trafficking, single-cell analyses of circulating immune cells from ETR-treated UC patients confirmed a significant reduction in B cells and pathogenic T cell subsets after ETR treatment providing an in-depth cellular characterization of S1PR modulation in UC patients thereby contributing to a better understanding of the key mechanism of action of ETR. However, these findings require validation in larger cohorts.
- Zeposia (ozanimod) / BMS
Impact of ozanimod on type III collagen turnover biomarkers and the association with ozanimod efficacy in patients with moderately to severely active ulcerative colitis: Results from the phase 3 True North study (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1695;
P3
Conclusion These data show that pts with UC who were treated with OZA had decreased plasma type III collagen degradation and turnover, with greater reductions in OZA responders than nonresponders. This further supports the evaluation of collagen type III fragments as potential markers of treatment response in pts with UC.
- Patients in trials of moderate-to-severe UC who are exposed to placebo are more likely to suffer harm than those receiving active treatment: The lack of clinical equipoise in traditional study designs (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1630;
Induction treatment responders re-randomized for maintenance to PBO experienced greater harms (i.e. lower NNH) than TT PBO patients. These findings raise concern about clinical equipoise in moderate-to-severe UC clinical trials and support ongoing efforts to design trials with active comparator arms and adaptive or platform methodologies.
- Velsipity (etrasimod) / Pfizer
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1628;
P2, P3
IRs were similar for most non?serious AEs across treatment groups, excluding headache and dizziness. Most non?serious AEs were short in duration and judged as not related to study treatment, suggesting they may not impact on the overall tolerability of etrasimod.
- Velsipity (etrasimod) / Pfizer
Etrasimod shows low risk of adverse events following concomitant use with opioids or antidepressants in patients with ulcerative colitis (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1617;
P3
Conclusion The incidence of AEs was low and comparable in patients receiving etrasimod with or without concomitant opioids or antidepressants. This analysis supports the low likelihood of clinically relevant drug
- Velsipity (etrasimod) / Pfizer
Efficacy and safety of etrasimod in patients with moderately to severely active UC in Japan: Integrated analysis of the phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN trials (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1457;
P3
Sandborn WJ et al. Lancet 2023; 401: 1159
- Entyvio (vedolizumab) / Takeda
Reduction of mucosal (active) eosinophils, B cells and T cells after vedolizumab therapy in patients with ulcerative colitis (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1278;
Vedolizumab therapy furthermore decreased several mucosal immune cell subsets that migrate to the gut through ?4?7-MAdCAM-1 binding. While the effect of vedolizumab on B cells and T cells was previously described, we have now potentially identified an additional eosinophil-reducing effect in the colon.
- | Ponvory (ponesimod) / J&J
Journal: The sphingosine-1-phosphate receptor 1 modulator ponesimod repairs cuprizone-induced demyelination and induces oligodendrocyte differentiation. (Pubmed Central) - Jan 24, 2024
Moreover, treatment with ponesimod alone or in combination with A971432, an S1P5 monoselective modulator, significantly increased primary mouse OPC differentiation based on O4 immunocytochemistry. In conclusion, S1P1 functional antagonism by ponesimod increases remyelination in the cuprizone model of demyelination and significantly increases OPC differentiation in
- | cisplatin / Generic mfg., paclitaxel / Generic mfg., fingolimod / Generic mfg.
Journal: FTY720 increases paclitaxel efficacy in cisplatin-resistant oral squamous cell carcinoma. (Pubmed Central) - Jan 24, 2024
In conclusion, S1P1 functional antagonism by ponesimod increases remyelination in the cuprizone model of demyelination and significantly increases OPC differentiation in FTY720 sensitizes cisplatin-resistant oral squamous cell carcinoma cells for paclitaxel.
- || S1PR agonist / Boehringer Ingelheim
Review, Journal: Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. (Pubmed Central) - Jan 23, 2024
Oral microbials have also demonstrated success in early phase studies. As new oral therapies emerge for the treatment of psoriasis, real-world data and comparative trials are needed to better inform their use among patients.
- | Zeposia (ozanimod) / BMS
Journal, Lymphopenia: Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia. (Pubmed Central) - Jan 22, 2024
As new oral therapies emerge for the treatment of psoriasis, real-world data and comparative trials are needed to better inform their use among patients. People with MS who have severe fingolimod-related lymphopenia and are clinically stable, can exhibit increased absolute lymphocyte counts when switched to ozanimod, while preserving clinical stability.
- | fingolimod / Generic mfg.
Retrospective data, Journal: Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study. (Pubmed Central) - Jan 22, 2024
People with MS who have severe fingolimod-related lymphopenia and are clinically stable, can exhibit increased absolute lymphocyte counts when switched to ozanimod, while preserving clinical stability. In this study, 10.5
- | Zeposia (ozanimod) / BMS
Journal: Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. (Pubmed Central) - Jan 22, 2024
It also details the nature and frequency of monitoring during treatment, which should be adapted to the individual patient based on preexisting risk factors and events that possibly occur during treatment. This review also provides insights into the patient characteristics and clinical scenarios best suited for ozanimod treatment based on its efficacy and safety profile and the comparative risks with other therapies.
- || Velsipity (etrasimod) / Pfizer
P2 data, Journal: Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial. (Pubmed Central) - Jan 21, 2024
P2
Etrasimod was effective for inducing EIHR in patients with UC. FCP and CRP may be useful, noninvasive biomarkers to monitor treatment response.
- | fingolimod / Generic mfg.
Journal, HEOR, Real-world evidence, Real-world: Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. (Pubmed Central) - Jan 20, 2024
By applying the same inclusion and exclusion criteria used in the RCT and employing appropriate methodology, we successfully replicated the RCT results with only minor discrepancies. Also, even if the confounding bias cannot be fully eliminated, conducting a rigorous target trial emulation could still yield valuable insights for comparative effectiveness research.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, Adverse events: Pharmacovigilance. Withdrawal and rebound effects: not just with psychotropic drugs (Pubmed Central) - Jan 17, 2024
This type of unintended effect, often underestimated, generally results from a drug-induced homeostatic imbalance that persists after the drug has been discontinued. Taking this risk into account right from the initial prescription should make it possible to prevent such complications, by encouraging intermittent use of the drug, or by applying a very gradual reduction in dosage when a regular treatment is stopped.
- | fingolimod / Generic mfg.
Journal: SPHK1/S1P/S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial-mesenchymal transition. (Pubmed Central) - Jan 16, 2024
Fingolimod was applied to suppress S1P/S1PR pathway...In conclusion, S1P levels in peritoneal effluent were correlated with the deterioration of peritoneal function. SPHK1/S1P/S1PR pathway played an important role in PF.
- | Journal, Real-world evidence, Real-world: Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study. (Pubmed Central) - Jan 15, 2024
SPHK1/S1P/S1PR pathway played an important role in PF. Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs.
- | Tysabri (natalizumab) / Biogen, Royalty
Journal: Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis. (Pubmed Central) - Jan 15, 2024
In active MS, an early postpartum treatment strategy should be determined well before delivery. Natalizumab/fingolimod-strategy reduced postpartum relapse hazard from month 3, but none diminished the early postpartum relapse hazard.
- | Mayzent (siponimod) / Novartis
Preclinical, Journal: Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up. (Pubmed Central) - Jan 15, 2024
The novel established imaging and analysis tools are suitable for assessing the dynamics of neuronal mitochondria ex vivo. Using these approaches, we showed that siponimod at 1 nM partially prevented oxidatively induced mitochondrial alterations in chronic brain slices.
- | Mayzent (siponimod) / Novartis
Journal, HEOR, Real-world evidence, Real-world: Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme. (Pubmed Central) - Jan 15, 2024
Cox regression analyses found participants with a nominated care partner had faster onboarding (HR 2.1, 95% CI [1.5-3.0]) and were more likely to continue self-reporting daily siponimod dosing than were those without a care partner (HR 2.2, 95% CI [1.3-3.7]). Despite the limitations of self-reported data and the challenges of the COVID-19 pandemic, this study provides insights into siponimod onboarding in Australia and demonstrates the positive impact of care partner support.
- | fingolimod / Generic mfg.
Journal: Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer's Disease Therapy. (Pubmed Central) - Jan 12, 2024
Herein, an intelligent oral brain-targeting nanoparticle (FTY@Man NP) constructed from a PLGA-PEG skeleton loaded with fingolimod (FTY) and externally modified with mannose was designed in combination with a glucose control strategy for the multitarget treatment of Alzheimer's disease (AD)...Notably, both in vitro and in vivo results have consistently demonstrated that the oral administration of FTY@Man NP could effectively traverse the multiple barriers, thereby exerting significant therapeutic effects. This breakthrough holds the promise of realizing a highly effective orally administered treatment for AD.
- | fingolimod / Generic mfg.
Journal: Risk of T lesions when discontinuing fingolimod: a nationwide predictive and comparative study. (Pubmed Central) - Jan 12, 2024
This nationwide study suggests that discontinuing fingolimod in some cases carries a risk of developing new T lesions, emphasizing the importance of clinical awareness. If feasible, clinicians should prioritize the prompt initiation of new disease-modifying therapies, particularly among young females.
- |||||| Zeposia (ozanimod) / BMS
Enrollment open, Trial primary completion date: SWITCH - ITA: A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jan 11, 2024
P=N/A, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
If feasible, clinicians should prioritize the prompt initiation of new disease-modifying therapies, particularly among young females. Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2024 --> Jan 2027
- || Zeposia (ozanimod) / BMS, Rinvoq (upadacitinib) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Review, Journal: Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review. (Pubmed Central) - Jan 11, 2024
Significant malformation risks were reported for tofacitinib, filgotinib, upadacitininb, and ozanimod in animal studies...In 78 upadacitinib-exposed pregnancies, there were 30 healthy babies, 15 terminations, 15 miscarriages, and 18 outcomes unknown...Human data from clinical trials and real-world observations do not show concerning data so far, but these are very limited. Currently, alternative treatments should be used for IBD during pregnancy.
- | Ocrevus (ocrelizumab) / Roche, Biogen
Journal: The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022. (Pubmed Central) - Jan 11, 2024
The trends of individual DMT prescriptions and costs differed between states particularly in Western Australia (WA), Tasmania and Northern Territory (NT). DMT prescriptions and costs continuously increased over the last decade, particularly for higher efficacy DMTs, and their trends differed between States/Territories.
- || Velsipity (etrasimod) / Pfizer
Enrollment open: A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants (clinicaltrials.gov) - Jan 11, 2024
P1, N=8, Recruiting, Sponsor: Pfizer
DMT prescriptions and costs continuously increased over the last decade, particularly for higher efficacy DMTs, and their trends differed between States/Territories. Not yet recruiting --> Recruiting
- ||| Lemtrada (alemtuzumab) / Sanofi
Journal, Adverse events: Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis. (Pubmed Central) - Jan 9, 2024
Our findings not only complement those observed in short-term clinical trials but also provide new insights that help inform the risk-benefit profile of the DMDs used to treat MS in clinical practice. The results of this study highlight the continued need for long-term, independent safety studies of the DMDs used to treat MS.
- ||||| Velsipity (etrasimod) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Jan 9, 2024
P3, N=341, Active, not recruiting, Sponsor: Everstar Therapeutics Limited
The results of this study highlight the continued need for long-term, independent safety studies of the DMDs used to treat MS. Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Oct 2024 | Trial primary completion date: Oct 2022 --> Jul 2024
- fingolimod / Generic mfg.
Fingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network (SPAN) (North 121 A-C) - Jan 9, 2024 - Abstract #ISC2024ISC_1151;
Fingolimod improved some functional outcomes for AG females and YHM both sexes. Testing new drugs in different preclinical populations provides additional information on efficacy beyond young, healthy animals and may be an essential step to improving clinical translation.
- | fingolimod / Generic mfg.
Journal: Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis. (Pubmed Central) - Jan 8, 2024
Screening for latent TB prior to commencing fingolimod should be considered on an individual basis. The management of TB in MS patients on DMT requires an interdisciplinary approach.
- | fingolimod / Generic mfg.
Preclinical, Journal: Fingolimod exerts neuroprotection by regulating S1PR1 mediated BNIP3-PINK1-Parkin dependent mitophagy in rotenone induced mouse model of Parkinson's disease. (Pubmed Central) - Jan 8, 2024
FTY720 restored the neurobehavioural functions and protein expression of PINK1, Parkin and BNIP3 in ROT-induced PD mice. The results obtained in our study suggest that FTY720 has a neuroprotective effect in ROT-induced mice model of PD via PINK1-Parkin mediated mitophagy.
- ||| fingolimod / Generic mfg.
Journal, Adverse events: Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project. (Pubmed Central) - Jan 7, 2024
The tool described in this study using the presence and relevance of elements of information is the first designed, validated and standardised method for the assessment of the quality of information of case reports in pregnancy pharmacovigilance data. This method confers less inter-rater variability compared with a quality assessment by experts of pregnancy-related pharmacovigilance data.
- | fingolimod / Generic mfg.
Journal: Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod. (Pubmed Central) - Jan 6, 2024
Cryptococcus infections are associated with immunosuppression, most often due to human immunodeficiency virus infection, and only 6 fingolimod-associated cutaneous infections have been reported in the literature. Patients with MS on immunosuppressant medication should be carefully screened for cutaneous infections.
- || Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Bioavailable central nervous system disease-modifying therapies for multiple sclerosis. (Pubmed Central) - Jan 6, 2024
To our knowledge, alemtuzumab, fumarates (dimethyl, diroximel, and monomethyl), glatiramer acetates, interferons, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, and teriflunomide are either limited to the periphery or insufficiently studied to confirm direct central nervous system effects in participants with multiple sclerosis. In contrast, cladribine and sphingosine 1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are central nervous system-penetrant and could have beneficial direct central nervous system properties.
- fingolimod / Generic mfg.
UNVEILING A RARE CASE OF FINGOLIMOD-RELATED CRYPTOCOCCAL MENINGITIS IN A MULTIPLE SCLEROSIS PATIENT () - Jan 4, 2024 - Abstract #SCCM2024SCCM_1284;
Treatment involves liposomal amphotericin B with flucytosine for 2 weeks, followed by fluconazole. Monitor for complications like IRIS, especially if immunosuppressant medication is stopped.
- || Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Review, Journal, Immunomodulating: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. (Pubmed Central) - Jan 4, 2024
More than half of the included studies were sponsored by pharmaceutical companies and this may have influenced their results. Further studies should focus on direct comparison between active agents, with follow-up of at least three years, and assess other patient-relevant outcomes, such as quality of life and cognitive status, with particular focus on the impact of sex/gender on treatment effects.
- | fingolimod / Generic mfg.
Journal: FTY720 Nanoformulation Induces O-GlcNacylation of Synuclein to Alleviate Synucleinopathy. (Pubmed Central) - Jan 4, 2024
The neuroprotective effect of our nanoformulation is attributed to the upregulation of tyrosine hydroxylase (TH), the PD therapeutic target, with behavioral improvement in animals against rotenone-induced PD deficits. The neuroprotective molecular insights revealed the camouflaged role of PP2A by endowing the OGT activity that induces O-GlcNacylation of synuclein in the reduction of synucleinopathy.
- | fingolimod / Generic mfg.
Journal: Letter to the editors: Development of malignant melanoma and squamous cell carcinoma in a patient receiving fingolimod treatment. (Pubmed Central) - Jan 3, 2024
The neuroprotective molecular insights revealed the camouflaged role of PP2A by endowing the OGT activity that induces O-GlcNacylation of synuclein in the reduction of synucleinopathy. No abstract available
- | Zeposia (ozanimod) / BMS
New P4 trial: Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study (clinicaltrials.gov) - Jan 3, 2024
P4, N=12, Not yet recruiting, Sponsor: Geert D'Haens
- | fingolimod / Generic mfg.
Preclinical, Journal: FTY720 requires vitamin B-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis. (Pubmed Central) - Jan 2, 2024
TCN2 functions as a chaperone for FTY720 and sphingosine, whose complex induces astrocytic CD320 internalization, suggesting a delivery mechanism of FTY720/sphingosine via the TCN2-CD320 pathway. Taken together, the B-TCN2-CD320 pathway is essential for the mechanism of action of FTY720.